Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCHE | P06276 | 3/20 | 0.37 |
| ▸ | BACE1 | P56817 | 8/20 | 0.37 |
| ▸ | CTSD | P07339 | 6/20 | 0.37 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.37 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.37 |
| ▸ | OGFRL1 | Q5TC84 | 1/20 | 0.37 |
| ▸ | PREP | P48147 | 1/20 | 0.35 |
| ▸ | CLK1 | P49759 | 1/20 | 0.35 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.35 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.35 |
| ▸ | BACE2 | Q9Y5Z0 | 3/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.34 |
| ▸ | BRD4 | O60885 | 1/20 | 0.34 |
| ▸ | AXL | P30530 | 1/20 | 0.34 |
| ▸ | MERTK | Q12866 | 1/20 | 0.34 |
| ▸ | AADAT | Q8N5Z0 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31486475 | 0.86 | PREP (0.43) | OPRM1OPRK1OGFRL1PREPMAPK14 | |
| SCHEMBL31486336 | 0.85 | AOC3 (0.42) | OPRM1OPRK1OGFRL1PREPMAPK14 | |
| SCHEMBL31486369 | 0.84 | PTK2 (0.42) | — | |
| Trifluoroacetic Acid SCHEMBL31486481 | 0.81 | F2 (0.40) | BACE1CTSDBACE2AADAT | |
| SCHEMBL31486384 | 0.81 | MAPK14 (0.35) | OPRM1OPRK1OGFRL1PREPMAPK14 | |
| SCHEMBL6734250 | 0.80 | F2 (0.44) | OPRM1OPRK1OGFRL1 | |
| SCHEMBL31486261 | 0.79 | MAPK14 (0.37) | OPRM1OPRK1OGFRL1PREPMAPK14 | |
| SCHEMBL6073947 | 0.77 | ACE (0.35) | PREPNPC1RAB9A | |
| SCHEMBL31486227 | 0.77 | JAK3 (0.43) | PREPRAB9A | |
| SCHEMBL31486546 | 0.77 | RPS6KB1 (0.39) | PREPMAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250122225-A1 | MASP-2 INHIBITORS AND METHODS OF USE | OMEROS CORPORATION (US) | 2025-04-17 | — | — | US | disclosed |
| WO-2025076476-A2 | MASP-2 INHIBITORS AND METHODS OF USE | OMEROS CORPORATION (US) | 2025-04-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250122225-A1 | MASP-2 INHIBITORS AND METHODS OF USE | MASP2, SPINT2, SERPINB1 | BCHE 2089/4885BACE1 428/4885CTSD 180/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.